Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-12-03 Capital/Financing Update
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Entitlement Offer and Placement Investor Presentation 53 pages 3.1MB
Capital/Financing Update Classification · 95% confidence The document is a detailed presentation prepared by Mesoblast Limited regarding a capital raising event, specifically an accelerated non-renounceable entitlement offer and an institutional placement. It includes information about the offer structure, pricing, discounts, and timelines. The text explicitly mentions terms like 'Capital Raising Presentation', 'Entitlement Offer', 'Placement', and details about the number of shares and pricing. There is no indication that this is a full financial report, audit, or earnings release. It is clearly a presentation focused on financing activities and capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2023-12-03 English
Appendix 3B Entitlement Offer and Placement 55 pages 1.1MB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard form used by entities listed on the Australian Securities Exchange (ASX) to announce a proposed issue of securities. It includes detailed information about the entity, the type of securities to be issued, and the nature of the offer (e.g., accelerated non-renounceable entitlement offer). The document is regulatory in nature, providing formal notification to the ASX about capital raising activities. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement of a capital/financing event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2023-12-03 English
Entitlement Offer Cleansing Notice 2 pages 183.8KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) related to a pro rata accelerated non-renounceable entitlement offer by Mesoblast Limited. It discusses the legal compliance and potential effects of the entitlement offer on control of the company. The document is an announcement about a capital raising activity (entitlement offer) and does not contain financial statements or detailed financial analysis. It is not a full report but a regulatory notice about a financing event. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3567 characters, which is consistent with a detailed announcement but not a full report.
2023-12-03 English
Trading Halt 2 pages 230.8KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Mesoblast Limited regarding a trading halt requested pending an announcement related to a proposed financing transaction. It references ASX Listing Rule 17.1 and states the halt is until an announcement is made or trading resumes. There is no financial data, report content, or detailed analysis present. The document is short (2079 characters) and serves as a notification about a trading halt, not the actual financing update or report. According to the rules, this is an announcement related to capital/financing activities but is not the detailed update itself. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-11-30 English
6-K
Regulatory Filings
2023-11-29 English
Amended Constitution 52 pages 1.0MB
Governance Information Classification · 100% confidence The document is titled 'Constitution' and is described as the amended version of the company's constitution adopted by special resolution at the 2023 Annual General Meeting. It contains detailed provisions about the company's governance, share capital, directors, meetings, and other corporate rules. It is not a financial report, earnings release, or management discussion. It is a governance document detailing internal rules and board structure. The document is lengthy (15,000 characters) and contains the full text of the constitution, not just an announcement or summary. Therefore, it fits the category of Governance Information (CGR).
2023-11-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.